** Shares of cosmetic drugmaker Evolus EOLS.O rise 3.7% to $14.88 in extended trade
** Co reports adjusted income of $6.7 million in Q4, compared with a year-ago loss of $3.7 million
** EOLS sees 2025 rev between $345 million and $355 million, versus Wall Street estimates of $351.3 million — LSEG
** Co says annual net revenue can reach at least $700 million by 2028
** EOLS rose 4.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。